An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37191665.
- Also identified by DOI 10.1158/1078-0432.CCR-23-0652.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PARP inhibitors exploit synthetic lethality in homologous recombination-deficient (HDR) cells and are standard-of-care treatment in newly diagnosed and relapsed epithelial ovarian cancer (EOC). A recent article demonstrated that a second course of olaparib can be safely administered to women with BRCA-mutated EOC. See related article by Morgan et al., p. 2602.
Medical subject headings
- Poly(ADP-ribose) Polymerase Inhibitors
- Ovarian Neoplasms